Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

This has demonstrated the potential of palbociclib in treating Alzheimer’s disease,” Chen said. The research shows the drug ...

A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the ...

(Bloomberg) -- Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer’s disease in 2025. Companies including Biogen Inc.

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

In one study, the company’s drug eased the agitation for Alzheimer’s patients. In a different study, there wasn’t a ...

Anavex Life Sciences is back with more data for a pill that it’s looking to get approved in a variety of neurodegenerative ...

A report from the U.S. FDA's Office of Inspector General is calling into question the thoroughness of the agency's ...

Recent studies implicate the immune system and a herpes virus as potential contributors to development of the disease.

While the Alzheimer’s market is projected to experience strong growth throughout the forecast period across the 8MM, unmet ...